The results showed that in the combined treatment group, arthritis severity remained stable after stopping treatment and remained significantly lower than that in the IgG control group at least until 15 days after cessation of treatment, whereas with TNFR‐Fc treatment alone, the disease relapsed shortly after stopping treatment and reached the control level (Figure 5A). This evidence concerns the gene TNFRSF1A and arthritic joint disease.